Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study

In patients with moderate-to-severe plaque psoriasis, biologic therapy has become a mainstay of treatment.Of recent agents, tildrakizumab is a monoclonal antibody targeting interleukin-23 (IL-23) that has been approved for treatment of moderate-to-severe plaque psoriasis in several countries worldwide [1].While phase III clinical trials and subsequent open-label extension studies have evaluated its efficacy and safety, realworld evidence involving patients from routine clinical practice is limited [1,2].While our group previously reported real-world drug survival outcomes of up to 3 years with tildrakizumab, this